|
CRF Announces Late Breaking Trials and First Report Investigations to be Presented at TCT 2013
Groundbreaking Clinical Trial Findings Will Be Reported As TCT Marks 25 Years Of Innovation In Interventional Cardiology
|
 |
The TCT 2013 meeting will be held in San Francisco from Oct 28-Nov 1 |
September 20, 2013 -- New York – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 28 - November 1, 2013 at The Moscone Center in San Francisco, California.
Clinical trial data and first report investigations presented at TCT often direct the course of patient therapies. The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.
Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Tuesday, October 29; Wednesday, October 30; and Thursday, October 31.
This year, TCT will also mark 25 years of innovation with a day-long look back at the significant contributions that interventional cardiology has made to patients with cardiovascular disease, as well as an inspiring look ahead at new therapies being developed for the not too distant future.
Media are invited to attend TCT; press credentials and registration information can be found here: http://www.tctconference.com/press/press-registration-form.html
TUESDAY OCTOBER 29, 2013
Late Breaking Trials
- SAFE-PCI: A Prospective, Registry-Based Randomized Trial of Radial Versus Femoral Vascular Access in Women Undergoing Diagnostic Cardiac Catheterization and PCI
- COREVALVE EXTREME RISK: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Self-Expanding Transcatheter Heart Valve in Patients with Severe Aortic Stenosis
- SORT-OUT VI: A Prospective, Randomized "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents Versus Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary Stents
WEDNESDAY, OCTOBER 30, 2013
Late Breaking Trials
- EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin Versus Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI Undergoing Primary PCI
- NORDIC-BALTIC BIFURCATION IV: A Prospective, Randomized Trial of a Two-Stent Strategy Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions
- TRYTON: A Prospective, Randomized Trial of a Dedicated Sidebranch Stent Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions
First Report Investigations
- LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries
- RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Versus Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis
- SMART-CASE: A Prospective, Randomized Trial of Conservative Revascularization Versus Aggressive Revascularization in Patients with Intermediate Lesions Undergoing PCI with Angiographic Guidance Alone
- HeartFlowNXT: A Prospective, Registry Evaluation of Noninvasive FFRCT Versus Invasive FFR
- ADVISE II: A Prospective, Registry Evaluation of iFR Versus FFR
- CHILL-MI: A Prospective, Randomized Trial of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction Undergoing Primary PCI
THURSDAY, OCTOBER 31, 2013
Late Breaking Trials
- OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy After PCI
- ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of 2 Years Versus 1 Year of Dual Antiplatelet Therapy After PCI
- DUTCH PEERS (TWENTE II): A Prospective, Randomized "All-Comers" Trial of Zotarolimus-Eluting Stents Versus Everolimus-Eluting Coronary Stents
First Report Investigations
- REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis
- FREEDOM: A Prospective, Randomized Trial of First Generation DES Versus CABG in Insulin and Non-Insulin Treated Diabetic Patients
- HYBRID: A Prospective, Randomized Trial of Hybrid Coronary Revascularization Versus Standard Surgical Revascularization in Multivessel Disease
- TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI
- GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction
- TATORT-NSTEMI: A Prospective, Randomized Trial of Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Segment Elevation Myocardial Infarction
To view the complete TCT agenda, visit: http://www.tctconference.com/agenda.html.
Receive updates on Twitter: http://twitter.com/TCTConference
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit www.crf.org and www.tctconference.com.
Source: Cardiovascular Research Foundation
|
